•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A05354 Summary:

BILL NOA05354
 
SAME ASNo Same As
 
SPONSORSteck
 
COSPNSR
 
MLTSPNSR
 
Amd §§3216, 3221 & 4303, Ins L
 
Requires health insurers to provide coverage without cost-sharing for opioid antagonists and devices; provides that no prior authorization of premedical review for coverage of such opioid antagonist is required.
Go to top

A05354 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          5354
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                    February 13, 2025
                                       ___________
 
        Introduced  by M. of A. STECK -- read once and referred to the Committee
          on Insurance
 
        AN ACT to amend the insurance  law,  in  relation  to  requiring  health
          insurers  to  provide  coverage without cost-sharing for opioid antag-
          onists and devices
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.  Subsection  (i)  of  section 3216 of the insurance law is
     2  amended by adding a new paragraph 40 to read as follows:
     3    (40) (A) (i) Every policy which  provides  coverage  for  prescription
     4  drugs  shall  include  coverage  for  at least one opioid antagonist and
     5  device.  No prior authorization or premedical review for coverage of  an
     6  opioid antagonist is required.
     7    (ii)  As used in this paragraph "opioid antagonist and device" means a
     8  drug approved by the food and drug administration  that,  when  adminis-
     9  tered,  negates  or  neutralizes in whole or in part the pharmacological
    10  effects of an opioid in the body. "Opioid antagonist" shall  be  limited
    11  to medications approved by the department of health for such purpose.
    12    (B)  The  coverage  mandated  by  this  paragraph shall include opioid
    13  antagonists prescribed or dispensed via standing order or  collaborative
    14  practice agreement intended for use on patients other than the insured.
    15    (C)  A policy shall not impose a deductible, co-insurance, co-payment,
    16  or any other cost-sharing requirement on such coverage provided pursuant
    17  to this paragraph.
    18    § 2. Subsection (l) of section 3221 of the insurance law is amended by
    19  adding a new paragraph 7-c to read as follows:
    20    (7-c) (A) (i) Every policy which provides  coverage  for  prescription
    21  drugs  shall  include  coverage  for  at least one opioid antagonist and
    22  device.  No prior authorization or premedical review for coverage of  an
    23  opioid antagonist is required.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD07388-02-5

        A. 5354                             2
 
     1    (ii)  As used in this paragraph "opioid antagonist and device" means a
     2  drug approved by the food and drug administration  that,  when  adminis-
     3  tered,  negates  or  neutralizes in whole or in part the pharmacological
     4  effects of an opioid in the body. "Opioid antagonist" shall  be  limited
     5  to medications approved by the department of health for such purpose.
     6    (B)  The  coverage  mandated  by  this  paragraph shall include opioid
     7  antagonists prescribed or dispensed via standing order or  collaborative
     8  practice agreement intended for use on patients other than the insured.
     9    (C)  A  group  or  blanket  policy subject to this paragraph shall not
    10  impose a deductible, co-insurance, co-payment, or any other cost-sharing
    11  requirement on such coverage provided pursuant to this paragraph.
    12    § 3. Section 4303 of the insurance law is  amended  by  adding  a  new
    13  subsection (ww) to read as follows:
    14    (ww) (1) (A) Every policy that is issued, amended, renewed, effective,
    15  or  delivered  on  or  after  January first, two thousand twenty-six and
    16  provides coverage for prescription drugs shall include coverage  for  at
    17  least  one  opioid  antagonist  and  device.   No prior authorization or
    18  premedical review for coverage of an opioid antagonist is required.
    19    (B) As used in this subsection "opioid antagonist and device" means  a
    20  drug  approved  by  the food and drug administration that, when adminis-
    21  tered, negates or neutralizes in whole or in  part  the  pharmacological
    22  effects  of  an opioid in the body. "Opioid antagonist" shall be limited
    23  to medications approved by the department of health for such purpose.
    24    (2) A contract subject to this subsection shall not impose  a  deduct-
    25  ible,  coinsurance,  copayment, or any other cost-sharing requirement on
    26  such coverage provided pursuant to this subsection.
    27    § 4. This act shall take effect immediately and shall apply  to  poli-
    28  cies  and  contracts issued, renewed, modified, altered or amended on or
    29  after such effective date.
Go to top